Applied Genetic Technologies Corp (AGTC) Drops 6.94% on January 11

Equities Staff |

Applied Genetic Technologies Corp (AGTC) was one of the Russell 2000's biggest losers for Monday January 11 as the stock slid 6.94% to $15.83, a loss of $-1.18 per share. Starting at an opening price of $17.03 a share, the stock traded between $15.54 and $17.16 over the course of the trading day. Volume was 162,453 shares over 1,810 trades, against an average daily volume of 166,788 shares and a total float of 18 million.

The losses send Applied Genetic Technologies Corp down to a market cap of $285 million. In the last year, Applied Genetic Technologies Corp has traded between $25.42 and $10.89, and its 50-day SMA is currently $16.72 and 200-day SMA is $17.16.

Applied Genetic Technologies Corp is a clinical-stage biotechnology company. It is developing gene therapy products designed to transform the lives of patients with severe diseases in ophthalmology.

Applied Genetic Technologies Corp is based out of Alachua, FL and has some 35 employees. Its CEO is Susan B. Washer.

For a complete fundamental analysis analysis of Applied Genetic Technologies Corp, check out Equities.com’s Stock Valuation Analysis report for AGTC. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Knightscope

Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.

Spotify

Spotify is a online music service offering providing digital content from a range of record labels and artists. Users can browse through the interface by artist, album, genre, playlist, record…